Biosig Technologies (BSGM) 1.6000 $BSGM
BioSig Technologies Signs Agreement to Conduct Pre Clinical Studies at UCLA
GlobeNewswire - Wed Jul 29, 7:00AM CDT
BioSig Technologies (OTCQB:BSGM), a medical device company developing PURE EP(TM), a proprietary technology platform designed to improve the fidelity of clinical signals available for electrophysiology (EP) procedures, today announced it has signed a Sponsored Research Agreement with The Regents of The University of California at Los Angeles ("UCLA"
to conduct preclinical evaluation of BioSig's PURE EP(TM) System in a ventricular tachycardia (VT) model.
BioSig Technologies, Inc. Appoints David Weild to Its Board of Directors as Audit Committee Chairman
GlobeNewswire - Tue May 26, 7:00AM CDT
BioSig Technologies, Inc. (OTCQB:BSGM) today announced that it has appointed David Weild to the Board of Directors, effective immediately. Mr. Weild has been elected to Chair the Audit Committee of the Board as the Company prepares to uplist to a National Stock Exchange.
BioSig Technologies to Present at the Marcum MicroCap Conference in New York on May 27
GlobeNewswire - Wed May 20, 7:20AM CDT
BioSig Technologies (OTCQB:BSGM), a medical device company developing PURE EP(TM) a proprietary technology platform designed to improve the clarity of clinical signals available for electrophysiology (EP) procedures, today announced that it will be present at the 2015 Marcum MicroCap Conference on Wednesday and Thursday, May 27-28, 2015 in New York City at the Grand Hyatt Hotel.
Michele Chin-Purcell, Ph.D., to Join BioSig Technologies as Vice President, Quality and Regulatory Affairs
GlobeNewswire - Mon May 11, 7:00AM CDT
BioSig Technologies (OTCQB:BSGM), a medical device company developing PURE EP(TM) a proprietary technology platform designed to improve the clarity of clinical signals available for electrophysiology (EP) procedures, today announced Michele Chin-Purcell, Ph.D., will be joining the company as Vice President, Quality and Regulatory Affairs. Dr. Chin-Purcell has over twenty years of experience in Research, Quality and Regulatory Affairs in the life sciences.
BioSig Executive Leadership to Attend Heart Rhythm Society's 36th Annual Scientific Sessions, May 13 - 16, 2015 in Boston, MA
GlobeNewswire - Tue Apr 28, 7:02AM CDT
BioSig Technologies (OTCQB: BSGM) executive leadership will be attending the Heart Rhythm Society's 36th Annual Scientific Sessions from May 13 - 16 in Boston, Massachusetts.
BioSig Technologies to Open Its Headquarters in Minneapolis
GlobeNewswire - Tue Apr 14, 7:00AM CDT
BioSig Technologies (OTCQB:BSGM), a medical device company developing PURE EP(TM) System, a proprietary technology platform designed to improve the clinical outcomes of electrophysiology procedures, today announced the opening of its second location and headquarters in Minneapolis, Minnesota. The Company will maintain its existing office based in Los Angeles, California, which will be devoted to research and development.
BioSig Retains Donohoe Advisory Associates LLC
Marketwired - Fri Apr 10, 7:00AM CDT
BioSig Technologies (OTCQB: BSGM) today announced that it has retained Donohoe Advisory Associates LLC of Rockville, Maryland to advise and assist the Company in its efforts to obtain a listing on a national securities exchange.
BioSig Technologies Announces the Appointment of Jerome B. Zeldis to Its Board of Directors
Marketwired - Thu Apr 09, 12:00PM CDT
BioSig Technologies (OTCQB: BSGM), today announced that Dr. Jerome B. Zeldis has joined the Company's Board of Directors, effective immediately. Dr. Zeldis has agreed to chair the Nominating Committee at the next regularly scheduled Board meeting.
CELGZ: 1.74 (+0.04)
BioSig Technologies to Present at Innovation in Medtech Dublin 2015
Marketwired - Wed Apr 08, 7:01AM CDT
BioSig Technologies (OTCQB: BSGM), a leading medical device company, today announced that Gregory Cash, Chief Executive Officer will be presenting at the Innovation in Medtech conference in Dublin, Ireland on April 15, 2015. Medical device veteran, Gregory Cash, will join the industry-leading event to present its PURE EP(TM) System, a proprietary technology platform designed to improve the clinical outcomes of electrophysiology procedures.
BioSig Technologies Appoints Wall Street Veteran, Brian McLaughlin to Lead Corporate Finance and Investor Relations
ACCESSWIRE - Mon Apr 06, 6:25PM CDT
Seasoned Executive Appointed as Vice President of Corporate Finance and Investor Relations to Accelerate Corporate Growth
CEO Gregory D. Cash of BioSig Technologies, Inc. to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "HealthTech Talk"
Marketwired - Fri Apr 03, 6:15AM CDT
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company that has developed a proprietary technology platform designed to greatly improve the rapidly growing $3 billion electrophysiology (EP) marketplace, announced today that Chief Executive Officer (CEO), President, and Director Gregory D. Cash will be interviewed live on iHeart Radio's HealthTech Talk hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM tomorrow, at 3:00pm ET. In this exclusive interview, Mr. Cash will discuss its product PURE EP(TM) System which EP is designed to improve outcomes of EP studies and cardiac catheter ablation, shorten procedure times and reduce recurrence rates. We encourage all shareholders, analysts, industry professionals and interested parties to tune in live. The details and link to iHeart Radio's live worldwide stream are below.
BioSig Technologies Closes Private Placement
Marketwired - Wed Apr 01, 7:01AM CDT
BioSig Technologies (OTCQB: BSGM), a medical device company developing PURE EP(TM), a proprietary technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, today announced the Company closed a private placement of $4.009 million. Laidlaw & Co (UK) Ltd. served as the sole placement agent.
Jay Millerhagen Joins BioSig Technologies as Vice President, Clinical Affairs
Marketwired - Mon Mar 23, 7:00AM CDT
BioSig Technologies (OTCQB: BSGM), a medical device company developing PURE EP(TM) a proprietary technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, today announced Jay Millerhagen has been appointed Vice President, Clinical Affairs. Mr. Millerhagen has over 25 years of experience developing, evaluating and launching new medical technologies and therapies.
Jeffrey F. O'Donnell, Sr. Rejoins BioSig Technologies' Board of Directors
Marketwired - Thu Feb 05, 7:02AM CST
BioSig Technologies (OTCQB: BSGM), a medical device company that is developing its proprietary PURE EP(TM) technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, today announced Jeffrey F. O'Donnell, Sr. has rejoined BioSig's Board of Directors and will serve as Chairman of the Compensation Committee. Mr. O'Donnell sat on BioSig's Board of Directors from October 2011 through February 2014.
BioSig Technologies Engages PCG Advisory as Agency of Record
ACCESSWIRE - Mon Feb 02, 7:02AM CST
LOS ANGELES, CA & NEW YORK, NY / ACCESSWIRE / February 2, 2015 / BioSig Technologies (OTCQB: BSGM), a medical device company that is developing its proprietary PURE EP(TM) technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, today announced it has retained PCG Advisory as its agency of record for capital markets advisory services, strategic and tactical digital and social media communications and public relations advisory services.
BioSig Appoints Samuel J. Asirvatham, M.D. to Scientific Advisory Board
Marketwired - Thu Jan 15, 6:01AM CST
BioSig Technologies (OTCQB: BSGM), a medical device company that is developing its proprietary PURE EP(TM) technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, today announced it has appointed Samuel J. Asirvatham, M.D. to its Scientific Advisory Board.
BioSig Files International Patent Application - Systems and Methods for Evaluation of Electrophysiology Systems
Marketwired - Wed Jan 07, 8:01AM CST
BioSig Technologies (OTCQB: BSGM), a medical device company that has developed and is preparing to commercialize its proprietary PURE EP(TM) technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, announced today it has filed a Patent Cooperation Treaty (PCT) application for technology related to the method for evaluating the PURE EP System and existing EP recording systems.
BioSig Engages FDA Consulting Firm for 510(k) Approval & QA Advisory; Company Taps CRO Industry Leader Libra Medical
ACCESSWIRE - Mon Dec 01, 8:00AM CST
LOS ANGELES, CA / ACCESSWIRE / December 1, 2014 / BioSig Technologies (OTCQB: BSGM), a medical device company that has developed and is preparing to commercialize its proprietary PURE EP(TM) technology platform designed to greatly improve the clinical value of electrophysiological (EP) cardiac recordings, today announced it has retained Libra Medical, Inc. for Regulatory Affairs and Quality Assurance services in support of the Company's planned 510(k) application to the FDA for its PURE EP System.
BioSig Technologies, Inc. (OTCQB: BSGM), Which is Going Commercial to Improve Recording Signals Used to Treat Abnormal Heartbeats, is Featured in Flaherty Special Situation Newsletter
ACCESSWIRE - Tue Nov 25, 7:16AM CST
WEST HARRISON, NY / ACCESSWIRE / November 25, 2014 / The race for BioSig Technologies, Inc. (OTCQB: BSGM) to record abnormal heartbeat wave signals and significantly improve innovation-starved arrhythmia treatment is described in the November 20, 2014 issue of Flaherty Special Situation Newsletter. (Also in this issue is our Follow Up: Remembering the fairy tale life of one of America's first female financial writers, courageous Clare Reckert of The New York Times.)
BioSig Technologies Signs Agreement to Conduct Pre Clinical Studies at UCLA
GlobeNewswire - Wed Jul 29, 7:00AM CDT
BioSig Technologies (OTCQB:BSGM), a medical device company developing PURE EP(TM), a proprietary technology platform designed to improve the fidelity of clinical signals available for electrophysiology (EP) procedures, today announced it has signed a Sponsored Research Agreement with The Regents of The University of California at Los Angeles ("UCLA"
to conduct preclinical evaluation of BioSig's PURE EP(TM) System in a ventricular tachycardia (VT) model. BioSig Technologies, Inc. Appoints David Weild to Its Board of Directors as Audit Committee Chairman
GlobeNewswire - Tue May 26, 7:00AM CDT
BioSig Technologies, Inc. (OTCQB:BSGM) today announced that it has appointed David Weild to the Board of Directors, effective immediately. Mr. Weild has been elected to Chair the Audit Committee of the Board as the Company prepares to uplist to a National Stock Exchange.
BioSig Technologies to Present at the Marcum MicroCap Conference in New York on May 27
GlobeNewswire - Wed May 20, 7:20AM CDT
BioSig Technologies (OTCQB:BSGM), a medical device company developing PURE EP(TM) a proprietary technology platform designed to improve the clarity of clinical signals available for electrophysiology (EP) procedures, today announced that it will be present at the 2015 Marcum MicroCap Conference on Wednesday and Thursday, May 27-28, 2015 in New York City at the Grand Hyatt Hotel.
Michele Chin-Purcell, Ph.D., to Join BioSig Technologies as Vice President, Quality and Regulatory Affairs
GlobeNewswire - Mon May 11, 7:00AM CDT
BioSig Technologies (OTCQB:BSGM), a medical device company developing PURE EP(TM) a proprietary technology platform designed to improve the clarity of clinical signals available for electrophysiology (EP) procedures, today announced Michele Chin-Purcell, Ph.D., will be joining the company as Vice President, Quality and Regulatory Affairs. Dr. Chin-Purcell has over twenty years of experience in Research, Quality and Regulatory Affairs in the life sciences.
BioSig Executive Leadership to Attend Heart Rhythm Society's 36th Annual Scientific Sessions, May 13 - 16, 2015 in Boston, MA
GlobeNewswire - Tue Apr 28, 7:02AM CDT
BioSig Technologies (OTCQB: BSGM) executive leadership will be attending the Heart Rhythm Society's 36th Annual Scientific Sessions from May 13 - 16 in Boston, Massachusetts.
BioSig Technologies to Open Its Headquarters in Minneapolis
GlobeNewswire - Tue Apr 14, 7:00AM CDT
BioSig Technologies (OTCQB:BSGM), a medical device company developing PURE EP(TM) System, a proprietary technology platform designed to improve the clinical outcomes of electrophysiology procedures, today announced the opening of its second location and headquarters in Minneapolis, Minnesota. The Company will maintain its existing office based in Los Angeles, California, which will be devoted to research and development.
BioSig Retains Donohoe Advisory Associates LLC
Marketwired - Fri Apr 10, 7:00AM CDT
BioSig Technologies (OTCQB: BSGM) today announced that it has retained Donohoe Advisory Associates LLC of Rockville, Maryland to advise and assist the Company in its efforts to obtain a listing on a national securities exchange.
BioSig Technologies Announces the Appointment of Jerome B. Zeldis to Its Board of Directors
Marketwired - Thu Apr 09, 12:00PM CDT
BioSig Technologies (OTCQB: BSGM), today announced that Dr. Jerome B. Zeldis has joined the Company's Board of Directors, effective immediately. Dr. Zeldis has agreed to chair the Nominating Committee at the next regularly scheduled Board meeting.
CELGZ: 1.74 (+0.04)
BioSig Technologies to Present at Innovation in Medtech Dublin 2015
Marketwired - Wed Apr 08, 7:01AM CDT
BioSig Technologies (OTCQB: BSGM), a leading medical device company, today announced that Gregory Cash, Chief Executive Officer will be presenting at the Innovation in Medtech conference in Dublin, Ireland on April 15, 2015. Medical device veteran, Gregory Cash, will join the industry-leading event to present its PURE EP(TM) System, a proprietary technology platform designed to improve the clinical outcomes of electrophysiology procedures.
BioSig Technologies Appoints Wall Street Veteran, Brian McLaughlin to Lead Corporate Finance and Investor Relations
ACCESSWIRE - Mon Apr 06, 6:25PM CDT
Seasoned Executive Appointed as Vice President of Corporate Finance and Investor Relations to Accelerate Corporate Growth
CEO Gregory D. Cash of BioSig Technologies, Inc. to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "HealthTech Talk"
Marketwired - Fri Apr 03, 6:15AM CDT
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company that has developed a proprietary technology platform designed to greatly improve the rapidly growing $3 billion electrophysiology (EP) marketplace, announced today that Chief Executive Officer (CEO), President, and Director Gregory D. Cash will be interviewed live on iHeart Radio's HealthTech Talk hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM tomorrow, at 3:00pm ET. In this exclusive interview, Mr. Cash will discuss its product PURE EP(TM) System which EP is designed to improve outcomes of EP studies and cardiac catheter ablation, shorten procedure times and reduce recurrence rates. We encourage all shareholders, analysts, industry professionals and interested parties to tune in live. The details and link to iHeart Radio's live worldwide stream are below.
BioSig Technologies Closes Private Placement
Marketwired - Wed Apr 01, 7:01AM CDT
BioSig Technologies (OTCQB: BSGM), a medical device company developing PURE EP(TM), a proprietary technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, today announced the Company closed a private placement of $4.009 million. Laidlaw & Co (UK) Ltd. served as the sole placement agent.
Jay Millerhagen Joins BioSig Technologies as Vice President, Clinical Affairs
Marketwired - Mon Mar 23, 7:00AM CDT
BioSig Technologies (OTCQB: BSGM), a medical device company developing PURE EP(TM) a proprietary technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, today announced Jay Millerhagen has been appointed Vice President, Clinical Affairs. Mr. Millerhagen has over 25 years of experience developing, evaluating and launching new medical technologies and therapies.
Jeffrey F. O'Donnell, Sr. Rejoins BioSig Technologies' Board of Directors
Marketwired - Thu Feb 05, 7:02AM CST
BioSig Technologies (OTCQB: BSGM), a medical device company that is developing its proprietary PURE EP(TM) technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, today announced Jeffrey F. O'Donnell, Sr. has rejoined BioSig's Board of Directors and will serve as Chairman of the Compensation Committee. Mr. O'Donnell sat on BioSig's Board of Directors from October 2011 through February 2014.
BioSig Technologies Engages PCG Advisory as Agency of Record
ACCESSWIRE - Mon Feb 02, 7:02AM CST
LOS ANGELES, CA & NEW YORK, NY / ACCESSWIRE / February 2, 2015 / BioSig Technologies (OTCQB: BSGM), a medical device company that is developing its proprietary PURE EP(TM) technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, today announced it has retained PCG Advisory as its agency of record for capital markets advisory services, strategic and tactical digital and social media communications and public relations advisory services.
BioSig Appoints Samuel J. Asirvatham, M.D. to Scientific Advisory Board
Marketwired - Thu Jan 15, 6:01AM CST
BioSig Technologies (OTCQB: BSGM), a medical device company that is developing its proprietary PURE EP(TM) technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, today announced it has appointed Samuel J. Asirvatham, M.D. to its Scientific Advisory Board.
BioSig Files International Patent Application - Systems and Methods for Evaluation of Electrophysiology Systems
Marketwired - Wed Jan 07, 8:01AM CST
BioSig Technologies (OTCQB: BSGM), a medical device company that has developed and is preparing to commercialize its proprietary PURE EP(TM) technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, announced today it has filed a Patent Cooperation Treaty (PCT) application for technology related to the method for evaluating the PURE EP System and existing EP recording systems.
BioSig Engages FDA Consulting Firm for 510(k) Approval & QA Advisory; Company Taps CRO Industry Leader Libra Medical
ACCESSWIRE - Mon Dec 01, 8:00AM CST
LOS ANGELES, CA / ACCESSWIRE / December 1, 2014 / BioSig Technologies (OTCQB: BSGM), a medical device company that has developed and is preparing to commercialize its proprietary PURE EP(TM) technology platform designed to greatly improve the clinical value of electrophysiological (EP) cardiac recordings, today announced it has retained Libra Medical, Inc. for Regulatory Affairs and Quality Assurance services in support of the Company's planned 510(k) application to the FDA for its PURE EP System.
BioSig Technologies, Inc. (OTCQB: BSGM), Which is Going Commercial to Improve Recording Signals Used to Treat Abnormal Heartbeats, is Featured in Flaherty Special Situation Newsletter
ACCESSWIRE - Tue Nov 25, 7:16AM CST
WEST HARRISON, NY / ACCESSWIRE / November 25, 2014 / The race for BioSig Technologies, Inc. (OTCQB: BSGM) to record abnormal heartbeat wave signals and significantly improve innovation-starved arrhythmia treatment is described in the November 20, 2014 issue of Flaherty Special Situation Newsletter. (Also in this issue is our Follow Up: Remembering the fairy tale life of one of America's first female financial writers, courageous Clare Reckert of The New York Times.)
